Completed PHASE1 INTERVENTIONAL 4-arm NCT05135871

Study Evaluating the Pharmacokinetics of Mavacamten in Healthy Adult Chinese Subjects

An Open-Label, Parallel-Group, Single-Center Phase 1 Clinical Study to Evaluate the Pharmacokinetics of a Single Oral Dose of Mavacamten in Healthy Adult Chinese Subjects

Sponsor: LianBio LLC

Conditions Hypertrophic Cardiomyopathy

Interventions Mavacamten

Updated 7 times since 2021 Last updated: Jul 19, 2024 Started: Oct 31, 2021 Primary completion: Feb 5, 2022 Completion: Feb 28, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Hypertrophic Cardiomyopathy and is currently completed. LianBio LLC leads this study, which shows 7 recorded versions since 2021 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Aug 2024 — Sep 2024 [monthly]

Completed PHASE1
Jul 2024 — Aug 2024 [monthly]

Completed PHASE1
Sep 2022 — Jul 2024 [monthly]

Completed PHASE1
Apr 2022 — Sep 2022 [monthly]

Completed PHASE1

Status: Recruiting → Completed

▶ Show 2 earlier versions

Jan 2022 — Apr 2022 [monthly]

Recruiting PHASE1
Dec 2021 — Jan 2022 [monthly]

Recruiting PHASE1

First recorded

Oct 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

LianBio LLC

Data source: LianBio LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China